# Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

Study · id `cardio:ct-nct02786979` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02786979](<https://clinicaltrials.gov/study/NCT02786979>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02786979

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 190 participants.

## Technical summary

Registry record NCT02786979. Randomized; no masking; primary purpose prevention. Start 2010-07 (registry gives no type); primary completion 2013-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 190 participants (enrolled count; ClinicalTrials.gov record NCT02786979, source copy `cardio:ctgov-nct02786979-2016-06-21`, retrieved 2026-10-26)
- Start date: 2010-07 (registry gives no type) (ClinicalTrials.gov record NCT02786979, source copy `cardio:ctgov-nct02786979-2016-06-21`, retrieved 2026-10-26)
- Primary completion: 2013-01 (actual) (ClinicalTrials.gov record NCT02786979, source copy `cardio:ctgov-nct02786979-2016-06-21`, retrieved 2026-10-26)
- Completion: 2013-01 (actual) (ClinicalTrials.gov record NCT02786979, source copy `cardio:ctgov-nct02786979-2016-06-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02786979, source copy `cardio:ctgov-nct02786979-2016-06-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02786979-2016-06-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Beraprost
- Intervention (Drug): Aspirin
- Lead sponsor: Astellas Pharma Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: 02c2d9342b4c76b4d3eceb9b2de3569987b6b1b408afbb09aa0d6277054f5de8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
